Our preclinical research service areas, including disease modeling, target validation, in vitro pharmacology, immunotoxicology, product characterization, cell engineering and biosimilars, leverage our expertise and advanced methodologies to support all stages of therapeutic development and drive your drug development program forward.
We specialize in cutting-edge assay design using advanced platforms, patented technologies, and state-of-the-art equipment. With a team of experts, we address the challenges of evolving therapeutic modalities, making us the ideal partner for your development needs.
Explore our core immunology research services for more information.
Advance with confidence. We design bespoke in vitro disease models that reflect complex immune interactions, so you can validate targets and define mechanisms of action to prioritize the most promising therapeutic candidates.
Understand your molecule’s true potential. Our in vitro pharmacology assays reveal potency, efficacy, and signaling data that guide rational design, helping you refine biologic and immunotherapeutic candidates before clinical testing.
Mitigate immune-related risks early. Using primary human immune cells and cell-based systems, our predictive immunotoxicology assays identify potential safety concerns to support smarter, safer development decisions.
We characterise our products through detailed analysis of their biological function and molecular binding. Functional studies confirm activity, specificity, and potency, while binding assays define affinity, kinetics, and target engagement. Together, these assessments ensure consistent performance and verified mechanism of action.
We build the cell based tools and models that you need to understand your molecule. Our custom-engineered cells and cell lines enable you to uncover binding, signalling, and mechanism-of-action insights with precision and reproducibility.
Achieve confidence in comparability. Our analytical and functional biosimilar assays are deigned to deliver data to demonstrate biosimilarity in support of regulatory submissions. Combined with complex primary immune cell assays that confirm mechanism of action and reduce the need for clinical efficacy studies, we de-risk development and accelerate approval.
As a pharmaceutical contract research organization, RoukenBio provides drug development services globally. Our scientific partners are based mainly in the USA—particularly in Massachusetts (Boston, Cambridge) and California (San Francisco and San Diego)—Canada (from Vancouver up to Seattle), the UK, and Europe.
Difficulty doesn’t deter us; it inspires us. Give us a problem, and we’ll find your solution. Our versatile specialists embrace every obstacle as an opportunity to showcase our innovative thinking and problem-solving prowess.
